17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

Inclusion Criteria:

* Histologically or cytologically confirmed diagnosis of 1 of the following hematologic malignancies:

  * Acute myeloid leukemia or acute lymphoblastic leukemia

    * Not a candidate for potentially curative therapy
    * WBC ≤ 10,000/mm\^3 OR WBC ≤ 40,000/mm\^3 that is stable for 5 days (hydroxyurea allowed)
    * No acute promyelocytic leukemia
  * Non-Hodgkin's lymphoma (NHL), including 1 of the following subtypes:

    * Small lymphocytic lymphoma
    * Marginal zone lymphoma
    * Lymphoplasmacytic lymphoma
    * Follicular lymphoma
    * Mantle cell lymphoma
    * Diffuse large B-cell lymphoma
    * Anaplastic large cell lymphoma
    * Peripheral T-cell lymphoma
    * Extranodal NK/T cell lymphoma (nasal and nasal type)
    * Enteropathy-type T-cell lymphoma
    * Hepatosplenic T-cell lymphoma
    * Angioimmunoblastic T-cell lymphoma
    * Subcutaneous panniculitis-like T-cell lymphoma
  * Chronic lymphocytic leukemia (CLL)
* Patients with NHL or CLL must meet the following criteria:

  * Ineligible for, or refused potentially curative stem cell transplantation
  * Transformed lymphoma/Richter's transformation, defined as the transformation of low-grade lymphoma, including follicular lymphoma, CLL, or small lymphocytic lymphoma to high-grade lymphoma (i.e., diffuse large cell lymphoma) allowed at time of transformation
  * Evidence of ≥ 50% bone marrow involvement at the time of enrollment OR tumor tissue accessible for biopsy (for patients enrolled after the maximum tolerated dose \[MTD\] is determined)
  * Absolute neutrophil count ≥ 1,000/mm\^3
  * Platelet count ≥ 100,000/mm\^3
* Relapsed or refractory disease
* Willing to undergo serial bone marrow biopsy (for patients enrolled after the MTD is determined)
* No untreated or active CNS leukemia or lymphoma
* Performance status - ECOG 0-2
* At least 12 weeks
* Bilirubin ≤ 1.5 mg/dL
* AST and ALT ≤ 2.5 times upper limit of normal
* Creatinine ≤ 2.0 mg/dL
* No uncontrolled cardiac disease
* No New York Heart Association class III-IV symptomatic congestive heart failure
* No unstable angina pectoris
* No serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation \> 3 beats in a row) within the past 6 months
* No other uncontrolled cardiac arrhythmia or requiring antiarrhythmic drugs
* No myocardial infarction within the past year
* No active ischemic heart disease within the past year
* No congenital long QT syndrome
* No left bundle branch block
* QTc ≥ 450 msec (for men) or 470 (for women) on ECG/EKG
* No history of LVEF \< 50% by MUGA or echocardiogram
* Resting ejection fraction ≥ 50% by MUGA or echocardiogram
* No prior history of cardiac toxicity after receiving anthracycline therapy (e.g., doxorubicin hydrochloride, daunorubicin hydrochloride, or mitoxantrone hydrochloride)
* No uncontrolled pulmonary disease
* No symptomatic pulmonary disease requiring oxygen or medications
* DLCO (i.e., oxygen diffusion capacity) ≥ 80% on pulmonary function testing
* Resting and exercise oxygen saturation ≥ 90% by pulse oximetry
* No ongoing pulmonary symptoms ≥ grade 2 including any of the following:

  * Dyspnea on or off exertion
  * Paroxysmal nocturnal dyspnea
  * Significant pulmonary disease including chronic obstructive or restrictive pulmonary disease
  * No prior history of pulmonary toxicity after bleomycin or carmustine
* No Medicare requirement for home oxygen (e.g., Resting O\_2 saturation ≥ 90% or desaturation to ≥ 90% with exertion)
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* HIV negative
* No preexisting sensory or motor peripheral neuropathy ≥ grade 2
* No history of allergic reaction to eggs
* No ongoing or active infection
* No psychiatric illness or social situation that would preclude study compliance
* No other uncontrolled illness
* Prior stem cell transplantation for relapsed or refractory disease allowed
* At least 2 weeks since prior immunotherapy and recovered
* At least 2 weeks since prior chemotherapy (excluding hydroxyurea) and recovered
* No other concurrent chemotherapy
* No concurrent routine corticosteroids except for treatment of other medical problems (e.g., pulmonary, rheumatologic, or adrenal disorders)
* At least 2 weeks since prior radiotherapy and recovered
* No prior radiotherapy that potentially included the heart in the field (e.g., mantle)
* No prior history of chest radiation
* No concurrent palliative radiotherapy
* At least 2 weeks since prior investigational therapy
* Prior bortezomib allowed
* No other concurrent commercial or investigational agents or therapies for the malignancy